Publications 2017 – 2014

| 2017 | 2016 | 2015 | 2014 | 2013 thru 2010 | 2009 thru 2006 | 2005 thru 2001 |

2017

  1. Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D, Shah K. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci U S A. 2017 Jul 14. pii: 201700363. doi: 10.1073/pnas.1700363114. PMID: 28710334
  2. Ignatius MS, Hayes MN, Lobbardi R, Chen EY, McCarthy KM, Sreenivas P, Motala Z, Durbin AD, Molodtsov A, Reeder S, Jin A, Sindiri S, Beleyea BC, Bhere D, Alexander MS, Shah K, Keller C, Linardic CM, Nielsen PG, Malkin D, Khan J, Langenau DM. The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep. 2017 Jun 13;19(11):2304-2318. doi: 10.1016/j.celrep.2017.05.061. PMID: 28614716
  3. Zhu Y, Bassoff N, Reinshagen C, Bhere D, Nowicki MO, Lawler SE, Roux J, Shah K. Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Sci Rep. 2017 Jun 1;7(1):2602. doi: 10.1038/s41598-017-02483-9. PMID: 28572590
  4. Jahan N, Lee JM, Shah K, Wakimoto H. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. Int J Cancer. 2017 May 31. doi: 10.1002/ijc.30811. PMID: 28567859

2016

  1. Shah K. Stem cell-based therapies for tumors in the brain: are we there yet? Neuro Oncol. 2016 Jun 9. pii: now096. PMID: 27282399

2015

  1. Zhu, Y., Choi, S.H. and Shah, K. Receptor targeted antibodies for cancer therapy. Lancet Oncology. 2015; Nov;16(15):e543-54. doi: 10.1016/S1470-2045(15)00039-X. PMID: 26545843
  2. Bagci-Onder, T., Du, W., Figueiredo, Martinez-Quintanilla, J., and Shah, K. Targeting breast to brain metastatic tumors with death receptor ligand expressing therapeutic stem cells. BRAINDoi:10.1093/brain/awv094. PMID: 25910782
  3. Bhere, D.,Shah, K. Stem Cell-Based Therapies for Cancer. Cancer Res. 2015;127:159-89. doi: 10.1016/bs .acr.2015.04.012. Epub 2015 May 19. PMID: 26093900
  4. Wehrenberg-Klee, E., Redjal, N., Leece, A., Turker, N.S., Heidari, P.,Shah, K., Mahmood U.PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance.Am J Nucl Med Mol Imaging. 2015 Jun 15;5(4):379-89. PMID: 26269775
  5. Choi, SH., Tamura, K., Khajuria, R., Lawler, J., and Shah, K. Antiangiogenic variant of TSP-1 targets TRAIL resistance in brain tumors. Molecular Therapy. 2015, 23(2):235-43. doi: 10.1038/mt.2014.214. PMID: 25358253
  6. Redjal, N., Zhu, Y. and Shah, K. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells. 33(1):101-10. doi: 10.1002/stem.1834. PMID: 25186100

2014

  1. Martinez-Quintanilla, J., Shah K. Response to “Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.” J Natl Cancer Inst. 2014 Dec 2;107(1):370. doi: 10.1093/jnci/dju370. Print 2015 Jan. No abstract available. PMID: 25473105
  2. Stuckey, DW., and Shah, K. Therapeutic stem cells for cancer. Nature Reviews Cancer. 2014 Oct;14(10):683-91. doi: 10.1038/nrc3798. Epub 2014 Sep 1. PMID: 25176333.
  3. Sullivan, J.P., Nahed, B.V., Madden, M.W., Oliveira, S.M., Springer, S., Bhere, D., Chi, A.S., Wakimoto, H., Kapur,R., Shah, K., Iafrate, J.A.,, Curry, W.T., Loeffler, J.S., Batchelor, T.T., Louis, D.N., Toner, M., Maheswaran, S. and Haber, D.A. Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression.Cancer Discov. 2014 Aug 19. [Epub ahead of print]. PMID: 25139148
  4. Redjal, N., Zhu, Y. and Shah, K. Combining systemically delivered chemotherapy with encapsulated stem cell TRAIL in resected brain tumors. Stem Cells. 2014. Sep 3. doi: 10.1002/stem.1834. [Epub ahead of print]
  5. Srivastava, J., Robertson, CL., Rajasekaran, D., Gredler, R., Siddiq, A., Emdad, L., Mukhopadhyay, ND., Ghosh, S., Hylemon, PB., Gil, G., Bhere, D., Shah, K., Subler, MA., Windle, JJ., Fisher, PB and Sarkar, D. Astrocyte Elevated Gene-1(AEG-1) Contributes to Hepatocellular Carcinoma by Regulating Retinoid X Receptor (RXR). Cancer Research. 2014; 74: 4364-77. doi: 10.1158/0008-5472.
  6. Kuruppu D, Brownell Al, Shah K, Mahmood U, Tanabe kk. Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability. Cancer Res. 2014 May 29. pii: canres.3472.2013. [Epub ahead of print]. PMID: 24876106
  7. Shah, K. Mesenchymal Stem Cells in Cancer Therapy .Elsevier. 2014 January PMID: 21740940
  8. Duebgen, M., Martinez-Quintanilla, J., Tamura, K., Hingtgen, S., Redjal, N., Wakimoto, H and Shah, K. Stem Cells Loaded With Multimechanistic Oncolytic herpes simplex virus variants for brain tumor therapy. Journal of Nat. Canc. Inst. 2014. PMID: 24838834
  9. Du, W, Uslar, L., Sevala, S. and Shah, K. Targeting c-Met receptor overcomes TRAIL-resistance in brain tumors. PLoS One. 2014 Apr 18. PMID: 24748276
  10. Zhu, Y and Shah, K. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. Cancer Biol Ther. 2014 March 25. PMID: 24658109